Dose-response relationship of the beta-adrenoceptor antagonist bisoprolol in patients with coronary heart disease and chronic obstructive bronchitis.
The effects of single, consecutively increased, oral doses of the beta-adrenoceptor antagonist bisoprolol (5, 10, 15, 20, 30 and 40 mg) on blood pressure, heart rate and bronchomotor tone were investigated in an open acute trial with 16 patients suffering from angina pectoris due to coronary heart disease and reversible chronic obstructive bronchitis. Even the lowest dose of bisoprolol (5 mg) caused a marked, long-lasting reduction in blood pressure and heart rate. After doses exceeding 20 mg, the incidence of an exaggerated pharmacodynamic effect on heart rate (beta 1-blockade) increased with dose. At doses above 30 mg, bisoprolol showed incipient impairment of bronchomotor function (beta 2-blockade) in individual patients. It is concluded that bisoprolol exhibits high beta 1-selectivity, i.e. a wide beta 1/beta 2 split, since blockade of bronchial beta 2-receptors only occurred at doses well above the therapeutically relevant dose range. The results may not be applicable to chronic treatment.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000403:Airway Resistance / Q000187:drug effects; D017298:Bisoprolol; D001794:Blood Pressure / Q000187:drug effects; D001991:Bronchitis / Q000188:drug therapy* / Q000503:physiopathology; D002908:Chronic Disease; D003327:Coronary Disease / Q000188:drug therapy* / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D004562:Electrocardiography; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D005996:Nitroglycerin / Q000627:therapeutic use; D011412:Propanolamines / Q000627:therapeutic use*
D000319:Adrenergic beta-Antagonists; D011412:Propanolamines; D005996:Nitroglycerin; D017298:Bisoprolol